Mmastodon WorldWorld first seen 20 h ago, last 4 h ago, peak #1
Imaavy becomes first approved treatment for warm autoimmune hemolytic anemia
Original: Recently, Imaavy (nipocalimab-aahu) becomes the first approved treatment for warm autoimmune hemolytic anemia (wAIHA). A
Imaavy (nipocalimab-aahu) has become the first approved treatment for warm autoimmune hemolytic anemia, a rare condition in which the immune system destroys red blood cells. Observers in the science and biotech community are calling it a significant win for the treatment of orphan diseases, noting that patients with wAIHA previously had no approved dedicated therapy. Approval of a drug for such a small patient population highlights growing momentum in rare disease drug development.
Why now: The first-ever regulatory approval for a condition that previously had no approved treatment is naturally drawing attention from rare disease and biotech communities.
Imaavynipocalimab-aahuwarm autoimmune hemolytic anemia
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/955074